CAR T-Cell Therapy A Malaysia
Kuna shirin ziyartar Malaysia don jinyar CAR T?
Samu kimantawa daga manyan asibitocin Malaysia.
CAR T cell therapy, a groundbreaking immunotherapy, is making strides in Malaysia’s medical landscape. This innovative treatment involves genetically modifying a patient’s T cells to recognize and attack cancer cells. Although initially available primarily in developed countries, Malaysia’s healthcare sector is embracing this cutting-edge approach. Several hospitals and research centers are exploring CAR T cell therapy’s potential, offering hope for patients with certain types of blood cancers, like leukemia and lymphoma. Challenges persist, including cost and infrastructure, but collaborations between institutions and industry aim to broaden access. As Malaysia advances in biotechnology and healthcare, CAR T cell therapy promises a transformative impact on cancer care.
MALAYSIAN Genomics Resource Center Bhd (MGRC) yana fatan ya sanya chimeric antigen receptor (CAR) T-cell far ana samun jiyya a Malesiya akan ƙasa da RM200,000 watau kusan dalar Amurka 45,000, wanda ɗan kaso ne na farashin jiyya a Turai da Amurka. Fatan CAR T-Cell far a Malaysia zai kawo farin ciki ga dubban marasa lafiya waɗanda ke fatan samun wannan ci gaban magani.
Hoto: CAR T An haɓaka maganin ƙwayar cuta don wasu nau'ikan ciwace-ciwace kuma
A cewar babban jami’in Genomics na kasar Malaysia Sasha Nordin, kamfanin ya hada hannu da kamfanin ICARTAB Biomedical Co Ltd na kasar Sin, wanda ke bunkasa fasahar keɓancewa na musamman don magance cututtuka masu tsauri, duk kuwa da cewa an riga an sami irin wannan maganin na cututtukan ruwa ko na jini a ƙasashen yammacin duniya.
"Haɓaka damar samun sabbin abubuwa wani ɓangare ne na umarninmu." Mun sami damar cimma yarjejeniya da ke ba mu damar ba da ita ga marasa lafiya a kudu maso gabashin Asiya don ɗan ƙaramin farashi.
A wata hira da The Malaysian Reserve jiya, ya ce, "Muna aiki don samar da shi a kan kasa da RM200,000 a kan US $ 400,000 (RM1.61 miliyan) a mafi ƙasƙanci a Turai da kuma Amurka."
MGRC za ta kasance mai rarraba maganin CAR T-Cell a Singapore, Brunei, Indonesia, Thailand, Vietnam, Cambodia, da Laos, ban da Malaysia.
A cewar Sasha Omar, kamfanin a halin yanzu yana da magunguna na shida daga cikin manyan cututtuka goma na yankin, wadanda suka hada da hanta, pancreatic, mesothelioma, esophagus, kwakwalwa, da ciwan ciki. Yana da'awar cewa CAR T-cell immunotherapy don m ciwon daji ba wani taro-samar warkewa.
Kowane magani a cikin farfaɗo ya keɓanta ga majiyyaci tunda ya haɗa da cire ƙwayoyin marasa lafiya da ba da damar T-cell mai haƙuri, muhimmin farin jini a cikin tsarin rigakafi, don gane ƙwayar cuta.
Sa'an nan kuma za a sake shigar da kwayar T-cell a cikin jikin majiyyaci don ganowa da yaki da kwayar cutar tantanin halitta, don hana shi yaduwa.
"Duk lokacin da muka sadu da majiyyaci, dole ne mu bi tsarin cancanta don tantance idan sun kasance 'yan takara nagari don maganin CAR T-Cell." Idan sun cika dukkan sharuɗɗan, za mu samar da ƙwayoyin T-kwayoyin na musamman ga majinyacin.
"Wannan shine dalilin da ya sa muka yi imanin yana da mahimmanci a sanya shi mai araha sosai." Za mu iya sarrafa farashin da ɗan kyau ta hanyar dacewa da namu lab, ”in ji shi.
Sasha Omar ta bayyana cewa, sabon dakin gwaje-gwaje na kamfanin zai fara aiki a karshen watan Maris na wannan shekara, kuma za a ci gaba da gudanar da ayyukan da wuri-wuri don biyan bukatar maganin.
Sabon yanki mai fadin murabba'in murabba'in 12,000 zai kasance a Kota Damansara, tare da dakin gwaje-gwajen zai dauki kusan murabba'in murabba'in 7,000 na sararin samaniya kuma tsarin ofis ya dauki sauran sarari.
Sabbin magungunan da aka haɓaka, irin su CAR-T (T-cell na chimeric antigen receptor), magunguna ne masu canza rayuwa ga mutanen da suka ƙare da yuwuwar zaɓin jiyya. Ana ba da waɗannan manyan jiyya ta hanyoyin da ba na al'ada ba, gami da dogayen ayyuka masu rikitarwa, da tsari sosai a cikin wuraren masu ba da lafiya. Masu ba da sabis za su amfana daga waɗannan jiyya ta hanyoyi daban-daban, daga haɓaka sunansu a matsayin ƙungiyoyi masu ƙwaƙƙwaran har zuwa samar da shirye-shirye masu fa'ida mai fa'ida. Koyaya, isar da waɗannan sabbin jiyya na ci gaba yana haifar da manyan ƙalubalen kuɗi da aiki idan ba a yi nazari da su a hankali ba kuma a shirya su.
Menene CAR T-Cell farfadowa (Masu karɓa na antim Chimeric)?
CAR T-Cell far wani nau'i ne na rigakafin rigakafi wanda ke amfani da ƙwayoyin T na musamman waɗanda suka kasance ɓangare na tsarin garkuwarmu zuwa yaki da cutar kansa. A sample of patients T cells are collected from the blood, then it is modified to produce special structures called chimeric antigen receptors (CAR) on their surface. When these modified CAR cells are reinfused in the patient, these new cells attack the specific antigen and kill the tumo Kwayoyin.
Ta yaya maganin C-T-Cell ke aiki?
CAR T-cell therapy takes help from body’s own immune system to attack and kill cancer cells. This is done by removing some specified cells from the blood of the patient, modifying them in the lab and re-injecting them into the patient. CAR T-cell therapy has produced very encouraging results in Non-Hodgkin lymphoma and thus approved by FDA.
'Yan takarar da suka dace don CAR T-Cell far
At present FDA has approved CAR T-Cell therapy for some forms of aggressive and refractory Non-Hodgkin lymphoma, Myeloma kuma ya koma baya kuma ya koma baya m lymphoblastic cutar sankarar bargo. Mara lafiya yana buƙatar aika cikakkun rahotannin likita don tabbatar da amfani da CAR T-Cell far don maganin sa.
Ka'idojin hadawa don C-T-cell far:
1. Marasa lafiya tare da CD19 + B-cell Lymphoma (Akalla haɗuwa 2 kafin lokaci chemotherapy tsarin mulki)
2. Yayi shekaru 3 zuwa 75
3. ECOG ci ≤2
4. Matan da zasu iya haihuwa dole ne suyi fitsari ciki gwajin da aka tabbatar kuma an tabbatar dashi mara kyau kafin maganin. Duk marasa lafiya sun yarda suyi amfani da ingantattun hanyoyin hana daukar ciki a lokacin gwajin har zuwa lokacin binsu na karshe.
Ka'idojin keɓancewa don C-T-cell far:
1. Hawan jini a cikin kwakwalwa ko suma
2. Rashin numfashi
3. Yada yaduwar jijiyoyin cikin jini
4. Hematosepsis ko Ciwo mai aiki mara ƙarfi
5. Rashin sarrafawa ciwon sukari
Fa'idodi na CAR T-Cell far
- > Motocin 5000 CAR T waɗanda kwararrun likitoci suka yi.
- Asibitoci a China sun haɓaka ƙarin nau'ikan CAR T Cell da suka haɗa da CD19 & CD 22 sannan kowace ƙasa a duniya.
- China tana gudanar da gwaji na asibiti sama da 300 a kan maganin CAR T Cell. Fiye da kowace ƙasa a duniya.
- Tasirin asibiti na CAR T Cell yayi kama da na Amurka ko wata ƙasa kuma wani lokacin mafi kyau.
Tsarin magani don CAR T-Cell far
- Cikakken kimantawa na mai haƙuri
- T-cell tarin daga jiki
- T-sel ana yin aikin injiniya a cikin lab
- T-Cells da aka ƙera halittarsu an ninka su ta hanyar amfani da su a cikin dakin bincike. Wadannan kwayoyin sun daskarewa sannan kuma a tura su zuwa cibiyoyin kulawa.
- Kafin infusing, mai haƙuri za a iya ba da ilimin kimiya don ciwon daji. Wannan yana taimaka aikin warkewa ta hanya mafi kyau.
- Ba da daɗewa ba bayan an gama shigar da ƙwayoyin cuta na CAR ta hanyar aiwatarwa wanda yayi kama da shigar jini.
- Akwai watanni 2-3 na lokacin dawowa ga mai haƙuri.
Tsarin lokaci don CAR T-Cell far
1. Jarrabawa & Gwaji: sati guda
2. Pre-treatment & T-Cell Collection: sati guda
3. T-Cell shiri & dawowa: makonni biyu-uku
4. Nazarin Inganci na 1: makonni uku
5. Nazari na Inganci na biyu: makonni uku
Farashin CAR T-Cell far a Malaysia
Farashin CAR T-Cell far a Malaysia zai kasance kusan tsakanin $ 45000 - 50,000 USD. Don cikakkun bayanai kan ƙa'idodin cancanta da ƙimar farashi don Allah a aika da rahoton likitan ku zuwa info@cancerfax.com tare da sunan ku da shekaru a matsayin batun.
Har ila yau karanta wannan: CAR T Cell far in India
Sakamakon sakamako na CAR T-Cell far
Sakamakon illa na CAR T-cell far sun haɗa da:
- Ciwon saki na Cytokine
A wasu lokuta, marasa lafiya na iya haifar da alamomin kamuwa da mura kamar zazzabi, sanyi, ciwon kai, tashin zuciya, amai, kujerun mara, da tsoka ko haɗin gwiwa. Hakanan yana iya haifar da ƙananan jini, wahalar numfashi, da saurin bugun zuciya. Wadannan cututtukan suna faruwa ne saboda sakin cytokines da kwayoyin kariya keyi yayin maganin C-T. Wadannan alamun alamun yawanci sauki ne, amma na iya zama mai haɗari da barazanar rai ga wasu marasa lafiya. - Ayyukan Neurology
Abubuwan da ke tattare da jijiyoyin jiki na iya faruwa kuma suna iya zama mai tsanani ga wasu marasa lafiya. Irin waɗannan abubuwan sun haɗa da encephalopathy (rauni na kwakwalwa da rashin aiki), rikicewa, wahalar magana, tashin hankali, kamuwa, bacci, yanayin canjin da aka samu da rashin daidaito. - Neutropaenia da Anemia
Wasu marasa lafiya na iya haɓaka ƙwayoyin cuta ko ƙananan ƙwanƙolin ƙwayoyin fata. Hakanan, ƙarancin jini ko ƙarancin ƙwayar ƙwayar jinin jini na iya faruwa saboda wannan maganin.
Abin farin ciki, yawancin waɗannan tasirin illa yawanci suna warware kansu ko kuma ana iya sarrafa su tare da amfani da su magunguna.
Yaya tasirin CAR T-Cell yake tasiri?
CAR T-cell far don maganin lymphoma da sauran cututtukan jini sun nuna kyakkyawan sakamako. Tun lokacin da aka yi maganin C-T-cell, yawancin marasa lafiya waɗanda suka sake dawowar ciwace-ciwacen jini suna da sakamako mai gamsarwa kuma babu shaidar cutar kansa. Hakanan ya taimaka wajen gyara marasa lafiyar wadanda a baya suka kasa amsa mafi yawan magungunan gargajiya na gargajiya.
Koyaya, ana buƙatar nazarin lokaci mai tsawo don yawan marasa lafiya don tabbatar da ingancin wannan magani. Experananan gwaje-gwajen za su iya taimakawa wajen gano yiwuwar tasirin illa da hanyoyin da suka dace don magance su.
Asibitoci da ke ba da maganin CAR T-cell a Malaysia
- Sunway Medical Center, Selangor
- Asibitin Columbia Asia, Kuala Lumpur
Ta yaya zan iya shan magani a Malaysia?